+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors



A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors



Cancer BioTherapy and Radiopharmaceuticals 13(4): 255-268



In the last several years, our laboratory has developed a new approach to the radioimmunotherapy of solid tumors, designated Tumor Necrosis Treatment (TNT), that exploits the presence of degenerating and necrotic cells within tumors by utilizing MAbs directed against universal, intracellular antigens. The first TNT MAb developed by our laboratory, designated TNT-1, was directed against nucleosomal determinants consisting of histone H1 and DNA. Since absolute tumor accretion of MAb is a critical determinant of antitumor efficacy in radioimmunotherapy, we sought to identify new antinuclear antibodies that displayed high tumor localization properties. In the present study, we describe a murine antinuclear antibody, TNT-3, which demonstrates 3-fold higher tumor uptake than TNT-1. Because of this characteristic, a chimeric derivative designated chTNT-3 was developed and evaluated for antigen binding and tumor targeting. ELISA studies using a series of nuclear antigens confirmed that TNT-3 is directed against single-stranded DNA and does not cross react with TNT-1. Immunohistology reveals predominantly nuclear staining reactivity in human tissues and tumors. Since it was shown by our laboratory that charge modification can significantly improve the pharmacokinetic performance of monoclonal antibodies, chTNT-3 was chemically modified with biotin to generate an improved therapeutic reagent designated chTNT-3/B. Comparative studies with unmodified MAb demonstrated that biotinylation significantly shortened its clearance time in mice and produced lower normal tissue levels, while maintaining an equal amount of uptake in tumor xenografts for up to 10 days. These in vivo characteristics suggest that chTNT-3/B is an improved TNT reagent for the radioimmunotherapy of solid tumors.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 045079356

Download citation: RISBibTeXText

PMID: 10850361

DOI: 10.1089/cbr.1998.13.255


Related references

Clinical radioimmunotherapy of solid tumors with chemically modified I-131 labeled chimeric TNT monoclonal antibodies. Journal of Nuclear Medicine 39(5 Suppl. ): 247P, 1998

Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors. Hybridoma and Hybridomics 20(5-6): 305-312, 2002

First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Annals of Oncology 28(4): 855-861, 2017

Genetically engineered derivatives of chimeric monoclonal antibody TNT-3 for the imaging of solid tumors. Proceedings of the American Association for Cancer Research Annual Meeting (41): 289-290, 2000

A chimeric TNT-3 monoclonal antibody mutant with rapid clearance for the immuno-scintigraphy of solid tumors. Journal of Nuclear Medicine 39(5 Suppl. ): 222P-223P, 1998

Radioimmunotherapy for breast cancer: treatment of a patient with I-131 L6 chimeric monoclonal antibody. International Journal of Biological Markers 6(4): 221-230, 1991

Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors. Clinical Cancer Research 17(21): 6888-6896, 2011

Radioimmunotherapy of orthotopically transplanted pancreatic cancer with 131I-labeled chimeric monoclonal antibody Nd2. Oncology Reports 6(1): 179-184, 1998

Radioimmunotherapy with Rhenium-186-labeled chimeric monoclonal antibody U36 in patients with head and neck cancer. Journal of Nuclear Medicine 40(5 Suppl. ): 65P, 1999

Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma. Laryngoscope 117(6): 1013-1018, 2007

Radioimmunotherapy of ovarian cancer with intravenously administered iodine-131 labeled chimeric MOv18 monoclonal antibody. Journal of Nuclear Medicine 40(5 Suppl. ): 216P, 1999

Radioimmunotherapy with 131I anti-CD20 chimeric monoclonal antibody for relapsed or refractory non-Hodgkins lymphoma. Journal of Nuclear Medicine 43(5 Suppl.): 115P-116P, 2002

Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors. Clinical Cancer Research 5(1): 51-60, 1999

Phase I/II radioimmunotherapy with I-131 labeled chimeric monoclonal antibody cG250 in patients with metastasized renal cell carcinoma. Journal of Nuclear Medicine 39(5 Suppl. ): 247P, 1998

Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. Journal of Nuclear Medicine 41(7): 1168-1176, 2000